Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07026279 · ClinicalTrials.gov registry record · Phase 1

A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer

A Phase 1 study of Pancreatic Cancer Metastatic, sponsored by Amplia Therapeutics Limited.

Recruiting
Registry status
Phase 1
Development phase
67
Enrollment target
7
Study locations

NCT07026279 is a Phase 1 study of Pancreatic Cancer Metastatic that is actively recruiting participants, run by Amplia Therapeutics Limited. The registered enrollment target is 67 participants, below the 124-participant average among 9 other Pancreatic Cancer Metastatic trials with a reported enrollment target (46% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07026279, a Phase 1 study of Pancreatic Cancer Metastatic, is actively recruiting participants, sponsored by Amplia Therapeutics Limited.

RECRUITING
Registry status
Phase 1
Development phase
67 participants
Enrollment target
7
Study locations

Study Summary

This study is testing narmafotinib, a type of drug called a focal adhesion kinase (FAK) inhibitor, when it is given in combination with 4 chemotherapy drugs in a regimen called FOLFIRINOX, to patients who have pancreatic cancer which has metastasised (spread). The study is being run in 2 parts. Part A will test increasing dose levels of narmafotinib in at least 3 people per dose at up to 4 dose levels to assess safety. Part B will test 2 of the dose levels from Part A in 20 people per dose, to select the best dose to take forward into future studies. Participants will take narmafotinib as oral capsules every day. They will also receive mFOLFIRINOX chemotherapy on Day 1 and and Day 15 of 28-day cycles.

Conditions Studied

Pancreatic Cancer Metastatic

Interventions

  • DRUG narmafotinib ascending doses
  • DRUG narmafotinib dose comparison

Study Locations (7)

California

  • UC Irvine Chao Family Cancer Centre - Orange

Florida

  • University of Florida Shands - Gainesville

New York

  • Icahn School of Medicine at Mount Sinai - New York

Ohio

  • Cleveland Clinic - Cleveland

Tennessee

  • Vanderbilt University Medical Centre - Nashville

New South Wales

  • GenesisCare - St Leonards

Victoria

  • Epworth Healthcare - Richmond

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2025-08-18
Est. Completion 2029-07
Phase Phase 1

Sponsor

Amplia Therapeutics Limited

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07026279

The ClinicalTrials.gov registry entry for NCT07026279 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 124-participant average among 9 other Pancreatic Cancer Metastatic trials with a reported enrollment target (46% lower). The listed sponsor is Amplia Therapeutics Limited, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Cancer Metastatic appearing as the primary indexed condition, and to 2 interventions - of which narmafotinib ascending doses is the first listed.

NCT07026279 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT07026279 about?

NCT07026279 is a clinical study titled "A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer". This study is testing narmafotinib, a type of drug called a focal adhesion kinase (FAK) inhibitor, when it is given in combination with 4 chemotherapy drugs in a regimen called FOLFIRINOX, to patients who have pancreatic cancer which has metastasised (spread). The study is being run in 2 parts. Par...

What is the current status of trial NCT07026279?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2025-08-18. Estimated completion is 2029-07.

What conditions does trial NCT07026279 study?

This clinical trial studies the following conditions: Pancreatic Cancer Metastatic.

What interventions are being tested in trial NCT07026279?

The interventions under investigation include: narmafotinib ascending doses (DRUG), narmafotinib dose comparison (DRUG).

Who is sponsoring clinical trial NCT07026279?

This trial is sponsored by Amplia Therapeutics Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07026279 being conducted?

This trial has 7 study locations across California, Florida, New York, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer Metastatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer Metastatic

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.